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Abstract
Around 2.5 million HIV-infected individuals failing first-line therapy qualify for boosted protease inhibitor (bPI)-
based second-line therapy globally. Major resistance mutations are rarely present at treatment failure in patients
receiving bPI and the determinants of failure in these patients remain unknown. There is evidence that Gag can
impact PI susceptibility. Here, we have sequenced Gag-Protease before and following failure in 23 patients in the
SARA trial infected with subtypes A, C, and D viruses. Before bPI, significant variation in Protease and Gag was
observed at positions previously associated with PI exposure and resistance including Gag mutations L449P,
S451N, and L453P and Protease K20I and L63P. Following PI failure, previously describedmutations in Protease
and Gag were observed, including those at the cleavage sites such as R361K and P453L. However, the emergence
of clear genetic determinants of therapy failure across patients was not observed. Larger Gag sequence datasets
will be required to comprehensively identify mutational correlates of bPI failure across subtypes.
The global scale up of antiretroviral (ART) therapyin resource-limited settings has reached an estimated 12.9
million HIV-infected individuals.1 Most patients initiate ART
on nucleoside reverse transcriptase inhibitor (NRTI) and
nonnucleoside reverse transcriptase inhibitor (NNRTI)-
containing regimens, with the protease inhibitor (PI) drug class
reserved for use in combination second-line therapies, as re-
commended by the WHO.2 Given the expense and toxicity of
PI-containing combination regimens, clinical trials have ex-
plored a number of simplification strategies.
The Boosted Protease Inhibitor Monotherapy as Main-
tenance Second-LineAntiretroviral Therapy inAfrica (SARA)
trial was a nested pilot study within the DART trial3 designed
to test whether boosted lopinavir (LPV/r) monotherapy (bPI-
mono) after an initial 24 weeks on second-line combination
therapy resulted in similar outcomes to continuation on com-
bination second-line therapy (CT).4 The trial demonstrated
noninferiority of LPV/r monotherapy in CD4+ T cell response
and rate of serious adverse events (SAEs), but viremia (‡50
copies/ml) wasmore common 24weeks after randomization in
the bPImono arm (23%CT vs. 40% bPImono, p= 0.01).Major
resistance mutations in protease were detected in 5/20 (25%)
bPImono participants with a viral load (VL) >1,000 copies/ml
at 24 weeks/last time point with successful genotyping (com-
pared to 0/8 CT).4 However, the causes of treatment failure in
the remaining patientswithoutmajor drug resistancemutations
are unknown.
Studies have shown that mutations in the protease enzyme
substrate Gag can also confer PI resistance, with mutations
identified in the cleavage sites and within the Gag polyprotein
subunits.5 Full-length Gag is not included in diagnostic ge-
notypic resistance assays, but in research settings we have
shown that the inclusion of Gag alongside its coevolved
Protease leads to susceptibility levels different from those
measured using protease alone.6,7 The genetic diversity ob-
served in Gag and Protease could result in polymorphisms
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overlapping PI resistance mutations in PI-naive, non-B sub-
type viruses and so could affect treatment outcome.8,9
Gag cleavage site mutations pretherapy were associated
with virological outcome in MONARK, a trial examining the
efficacy of LPV/r monotherapy as first-line treatment.10
MONARK enrolled patients infected mainly with subtype B
and CRF02_AG viruses predominant in Europe/North
America and West Africa, respectively. PI-naive subtype
CRF02_AG viruses from MONARK demonstrated reduced
PI susceptibility, hence we hypothesize that the presence of
Gag mutations as polymorphisms in PI-naive non-B subtypes
may predispose patients to treatment failure on PI mono-
therapy.8 Given the extensive sequence variation in Gag be-
tween HIV-1 non-B subtypes, it is necessary to examine the
role of Gag cleavage site mutations in PI failure in viruses
of other subtypes. We set out to investigate the role of Gag
cleavage site and noncleavage site mutations both present
pretreatment and evolving during PI exposure, as well as pro-
tease resistance mutations in PI treatment failure in subtypes
A, C, and D-infected patients enrolled in the SARA trial.
Twenty-eight patients experienced treatment failure in the
SARA trial with successful protease genotyping at failure. We
amplified by PCR and sequenced gag and protease genes by
population sequencing from pre-PI and treatment failure time
point samples for each patient. This study included 23 patients
from whom full-length gag was successfully amplified at both
time points: 16 patients randomized to the boosted PI mono-
therapy (bPImono) arm and 7 to the continuation therapy arm
(CT)4 (accession numbers KT351803–KT351848). The fre-
quency of mutations of interest in PI-naive viruses was ex-
amined and pairwise comparison performed to determine any
change in mutation frequency at the time of treatment
failure. Protease sequences were compared to the IAS list of
resistance mutations,11 Gag cleavage sites were compared
to the HIV-1 group M consensus sequence derived from
GenBank,9 and Gag noncleavage site mutations were ex-
amined by comparison to a list of previously described
mutations.5 Mutation frequency by subtype was determined
using the Los Alamos HIV database AnalyzeAlign tool
(www.hiv.lanl.gov/content/sequence/QUICK_ALIGNv2).
Pretherapy protease sequences were aligned and compared
to the IAS list of resistance mutations.11 None of the patients
harbored major PI resistance mutations at baseline, although
22/23 had minor PI resistance mutation(s) at baseline at the
following protease positions, some of which represent con-
sensus residues in specific non-B subtypes: 10, 16, 20, 33, 36,
60, 63, 69, 77, 89, and 93 (Supplementary Figure S1; Sup-
plementary Data are available online at www.liebertpub.com/
aid). Of note, mutations M36I and H69K were present in all
subtype A and C patient viruses and I93L was present in all
subtype C viruses, and were consensus residues in each sub-
type, respectively. Other common mutations included L10V
(observed in four patients), G16E (four patients), and K20R
(six patients), none of which was a consensus residue in sub-
type A, C, or D. Of particular relevance to this study were
mutations associatedwith resistance to boosted lopinavir: L10I
Table 1. Variation in Gag Cleavage Sites in Subtype A Viruses
Gag Cleavage Sites
MA/CA CA/p2 P2/NC NC/p1 p1/p6
128–137 359–368 373–382 428–437 444–453
Patient
number
Trial
arm
Time
point
VSQNY/
PIVQN
KARVL/
AEAMS
TXXIM/
MQRGN
ERQAN/
FLGKI
RPGNF/
LQSRP
1 CT Pre-PI -----/----- -----/----- HTH--/----- EK----/----- -----/P----
Failure -----/----- --K--/----- HTN--/----- -----/----- -----/P----
2 bPImono Pre-PI -----/----- -----/----- QTS--/--K-M -----/----- -----/P----
Failure -----/----- -----/----- HTN--/--K-M -----/----- -----/P----
3 bPImono Pre-PI -----/----- ---I-/----- QPN--/----- -----/----- -----/P-N-L
Failure -----/----- --KI-/----- Q-N--/----- -----/----- -----/P-N-L
4 bPImono Pre-PI -----/----- -----/----- QTN--/--RK-- -----/----- -----/P---PL
Failure -----/----- -----/----- QTN--/--K-- -----/----- -----/P----
5 bPImono Pre-PI -----/----- -----/----- NHAT---/----- -----/----- -----/P----
Failure -----/----- -----/----- H-N--/----- -----/----- -----/P----
6 bPImono Pre-PI -----/----- -----/----- NTK--/----- -----/----- -----/P---L
Failure -----/----- -----/----- NTK--/----- -----/----- -----/P---L
7 bPImono Pre-PI +----/-V--- -----/----- NTK--/----- -----/----- -----/P---L
Failure -----/-V--- -----/----- QPN--/----- -----/----- -----/P--RKL
8 bPImono Pre-PI -----/----- -----/----K PTN--/I---- -----/----- -----/P----
Failure -----/----- -----/----K PTN--/I---- -----/----- -----/P---L
9 bPImono Pre-PI -----/----- -----/----- QTNV-/----- -----/----- -----/P----
Failure -----/----- -----/----- QTSV-/----- -----/---RK- -----/P----
10 bPImono Pre-PI -----/----- -----/----- NTN--/----- -----/---RL -----/P----
Failure -----/----- -----/----- NTN--/----- -----/---RL -----/P----
11 CT Pre-PI -----/----- -----/----- PTN--/----- -----/----- -----/P----
Failure -----/----- -----/----- PTN--/----- -----/----- -----/P----
The sequence at each of the Gag cleavage sites is shown for the 11 patients infected with subtype A viruses, both at pre-PI therapy and at
treatment failure time points. Sequences were compared with the HIV-1 group M consensus sequence9 using HXB2 numbering. Where no
consensus residue was derived an X is present. Deletions are shown by + and mixed residues by superscript letters. Clinical trial arm is
shown: boosted PI monotherapy (bPImono) and continuation on combination therapy (CT).
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(three subtype A patients), L10V (one subtype A), K20R (five
subtype As and 1 subtype C), L33V (one subtype D), L63P
(one subtype A, two subtype Cs, and three subtype Ds).
The presence of minor resistance mutations in protease in
non-B subtypes has been widely reported: 63P is the con-
sensus residue in subtype D, L10I is present in 19% of sub-
type A sequences, and K20R is present in 22% of subtype A
and 15% of subtype Cs. Previous studies have shown that
they do not appear to affect in vitro susceptibility; however,
these studies have been performed using in vitro assays that
do not include patient-derived coevolved Gag, which can
substantially impact susceptibility.6,7,12
Pretherapy Gag cleavage site sequences for each patient
were manually compared with the consensus group M se-
quence to examine the frequency of previously described
mutations in these non-B subtypes that could predispose pa-
tients to treatment failure (Tables 1, 2, and 3). The p2/NC
cleavage site was the most variable as described previously,10
with all patients exhibiting at least one mutation in comparison
with consensus M in p2/NC. Variability was maintained when
comparison within subtype consensus at p2/NC was per-
formed, with 11/11 subtype A, 5/7 subtype C, and 3/5 subtype
D patients demonstrating at least one mutation in comparison
with their respective subtype consensus sequences at this
Table 2. Variation in Gag Cleavage Sites in Subtype C Viruses
Gag cleavage sites
MA/CA CA/p2 P2/NC NC/p1 p1/p6
128–137 359–368 373–382 428–437 444–453
Patient
number
Trial
arm
Trial week
failure (pre-PI)
VSQNY/
PIVQN
KARVL/
AEAMS
TXXIM/
MQRGN
ERQAN/
FLGKI
RPGNF/
LQSRP
12 CT Pre-PI -----/----- -----/----- N-N--/----- -----/----- -----/-----
Failure G----/----- -----/----- NTN--/----- -----/----- -----/-----
13 CT Pre-PI -----/----- -----/----- N-NV-/----- -----/----- -----/--N--
Failure -----/----- -----/----- N-NV-/----- -----/----- -----/--N--
14 CT Pre-PI -----/----- -----/----- H-A--/--KS- -----/----- -----/--N--
Failure -----/----- -----/----- NTN--/--KS- -----/----- -----/--N--
15 bPImono Pre-PI I----/----- -----/----- NSN-L/---S- -----/----- -----/--N--
Failure -----/----- -----/----- NSN-L/---S- ---V-/----- -----/--N--
16 CT Pre-PI -----/----- -----/----- NSN--/----- -----/----- -----/-----
Failure -----/----- -----/----- NSN--/----- -----/----- -----/-----
17 bPImono Pre-PI -----/----- -----/----- NSN--/----NK -----/----- -----/--N--
Failure -----/----- -----/----- NSN--/----- -----/----- -----/--N-L
18 bPImono Pre-PI -----/----- -----/----- NNNH--/---S- -----/----- -----/-----
Failure -----/----- -----/----- NNH--/---S- -----/----- -----/-----
The sequence at each of the Gag cleavage sites is shown for the seven patients infected with subtype C viruses, both at pre-PI therapy and
at treatment failure time points. Sequences were compared with the HIV-1 group M consensus sequence9 using HXB2 numbering. Where
no consensus residue was derived an X is present and mixed residues are shown in superscript letters. Clinical trial arm is shown: boosted PI
monotherapy (bPImono) and continuation on combination therapy (CT).
Table 3. Variation in Gag Cleavage Sites in Subtype D Viruses
Gag cleavage sites
MA/CA CA/p2 P2/NC NC/p1 p1/p6
128–137 359–368 373–382 428–437 444–453
Patient
number
Trial
arm
Trial week
failure (pre-PI)
VSQNY/
PIVQN
KARVL/
AEAMS
TXXIM/
MQRGN
ERQAN/
FLGKI
RPGNF/
LQSRP
19 CT Pre-PI -----/----- -----/----- QPN--/----- ED----/----VL -----/-----
Failure -----/----- -----/----- QSN--/----- -----/----V -----/-----
20 bPImono Pre-PI -----/----- -----/----- N-A--/----- -----/----- -----/-----
Failure -----/----- -----/----- N-A--/----- -----/----- -----/-----
21 bPImono Pre-PI -----/----- -----/----- SNTA--/----- -----/----- -----/-----
Failure -----/----- -----/----- -TA--/----- -----/----- -----/-----
22 bPImono Pre-PI -----/----- -----/----- NTA--/----- -----/----- -----/--N--
Failure -----/----- -----/----- NATA--/----- -----/----- -----/--N--
23 bPImono Pre-PI -----/----- -----/----- N-A--/----- -----/----- -----/--N--
Failure -----/----- -----/----- N-A--/----- -----/----- -----/--N--
The sequence at each of the Gag cleavage sites is shown for the five patients infected with subtype D viruses, both at pre-PI therapy and at
treatment failure time points. Sequences were compared with the HIV-1 group M consensus sequence9 using HXB2 numbering. Where no
consensus residue was derived an X is present and mixed residues are shown in superscript letters. Clinical trial arm is shown: boosted PI
monotherapy (bPImono) and continuation on combination therapy (CT).
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cleavage site. Excluding the p2/NC cleavage site, 18 of 23
patients had cleavage site mutations versus consensus M at
baseline (11/11 subtype A patients, 3/5 subtype D patients, and
4/7 subtype C patients) and 15 versus their respective subtype
consensus sequence (8/11 subtype A, 3/5 subtype D, and 4/7
subtype C). Four patients exhibited mutations in the Gag N
terminal cleavage sites, which were not subtype consensus
residues: two inMA/CA and two in CA/p2. At the C terminus,
17/23 patients had amino acid changes versus consensus M
includingmutations L449P, S451N, and P453L that previously
were associated with PI exposure and/or resistance.5
The L449Pmutationwas present in all patients infectedwith
subtypeA (n= 11), in keepingwith the finding of another study
reporting P as the consensus amino acid at position 449 in
subtype A.9 The cleavage site mutation S451N was found in
7/23 patients (4/7 subtype C, 2/5 subtype D, and 1/11 subtype
A), but is not a consensus residue in these subtypes. Mutation
P453Lwas present in 4/11 subtypeApatients, but again is not a
consensus residue in subtypes A, C, or D. Only 5/23 patients
had no cleavage site mutations in comparison with consensus
M outside of the p2/NC site (3/7 subtype C and 2/5 subtype D).
Multiple amino acid changes in Gag outside cleavage sites
have been reported to affect susceptibility to PIs and to be
associated with treatment failure. Therefore we manually
examined the sequences for the presence of these previously
described mutations in the pre-PI sequences.5 Several of
these mutations were present pre-PI therapy in our patient
cohort, at positions 12, 30, 62, 76, 79, 81, 371, 389, 401, and
456. E12K, described as accelerating the emergence of re-
sistance in concert with other Gag mutations, was the most
frequent, present in 21/23 patients, and is in fact the con-
sensus amino acid in most non-B subtypes.13 Mutations in the
matrix (MA) subunit described by Parry et al. were also
common with R76K in 13/23 patients (6/11 subtype A, 4/7
subtype C, and 3/5 subtype D) and Y79F in 10/23 patients
(3/11 subtype A, 4/7 subtype C, and 3/5 subtype D); in fact,
76K is the consensus residue in subtype D viruses.14
Pairwise comparisons of pre-PI and failure Gag-Protease
sequences from 23 patients were performed to identify amino
acid changes associated with PI exposure and treatment
failure. Changes in protease at failure in comparison with the
pre-PI sample were found in 17/23 patients (Table 4). Ex-
cluding the development or fixation of a mixed amino acid
position, 12/23 patients had a new mutation at treatment
failure. The major LPV resistance mutation I54V developed
at failure in two patients (6 and 8) and V82A in two additional
patients (4 and 15). Two patients developed a new minor
resistance mutation at failure (patient 3, K20R and 4, L10I)
and two patients had mutations at minor resistance position
63, though to different residues (16 to I and 11 to S).11
At the time of treatment failure 16 patients had Gag
cleavage site changes in comparison with baseline (excluding
fixation of mixed residues) at positions 128, 361, 373, 374,
375, 431, and 453 (Tables 2, 3, and 4). Of these, 13 patients
displayed a new change and 10 displayed a reversion to
consensus M amino acid; seven patients had both a new
mutation and a reversion. The p2/NC cleavage site displayed
the greatest variation between baseline and failure, with 12
patients displaying at least one amino acid change after PI
therapy (mostly at positions 373, 374, and 375). In patient 15,
the A431V mutation developed in the NC/p1 cleavage site at
failure with major mutation V82A, a coevolution that is
frequently observed.5 Of particular interest, two CSMs de-
veloped in two separate patients at the time of failure—
R361K (in two subtype A patients—1 and 3) and P453L (in
subtype A patient 8 and subtype C patient 17). To our
knowledge R361K has not been previously linked to PI re-
sistance or exposure, but P453L has been associated with PI
exposure in vitro, in vivo, and with PI resistance.5
Pairwise comparisons showed that 16 of 23 patients had at
least one amino acid change at previously described non-
cleavage site residues at treatment failure in comparison with
pre-PI. These changes occurred at the following positions in
Gag: 30 (n= 6 patients), 62 (n = 6), 75 (n = 2), 76 (n = 5), 79
(n = 4), 81 (n = 1), 112 (n= 1), 370 (n = 4), 371 (n= 1), 389
(n = 2), 390 (n= 1), 401 (n = 3), 456 (n = 1), and 468 (n = 4).
However, in general no consistent pattern of selection toward
specific amino acids at each position was observed across a
number of patients. For example, the R76K mutation has
previously been described as affecting PI susceptibility but
here selection from an R/K mix pre-PI to each of Q and R at
failure was observed in different patients, as well as R76K,
K76R/K, and K76R in three other patients.14 The develop-
ment of Y79F at failure was present in two patients, although
F79Y was also observed in a third, and T81A was also ob-
served at failure in a single patient. Mutations at positions 76,
79, and 81 were previously described in concert, but in this
patient cohort they were not observed in the same patients.14
We have demonstrated variation at baseline in Gag-
Protease of non-B viruses at sites of interest for PI resistance
and evolution at these sites during PI therapy. However, the
emergence of clear genetic determinants of therapy failure
across a number of patients was not observed. This may be
due to the limited number of patients available for each viral
subtype, as the intersubtype differences confound the search
for resistance mutations associated with treatment failure.
Another possibility is that given the large number of CTL
epitopes present in Gag, the HLA type of the patient would
affect the development of resistance mutations in Gag. We
also cannot rule out the role of other regions outside of Gag
and Protease in PI resistance, such as envelope,15 and the
potential role of unreported poor therapy adherence in
treatment failure. There is an urgent need for a greater un-
derstanding of PI therapy failure as these drugs become more
widely used in populations infected with divergent HIV-1
strains and further genotypic and phenotypic studies exam-
ining determinants of PI treatment failure in non-B subtypes
are required.
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